US 2026/0234247 A1Published application

Anti-lilrb1 and/or anti-lilrb2 antibodies and uses thereof

AssigneeLaekna Pharmaceutical Ningbo Co., Ltd.

InventorsRong WU, Chaojun CAI, Minhua ZHANG, Xiang-Ju Justin GU

Life of this patent

Estimating the term…

Abstract

Provided herein, in certain aspects, are antibodies that bind to LILRB1, and uses thereof. Also provided herein, in certain aspects, are antibodies that bind to LILRB2, and uses thereof. Also provided herein, in certain aspects, are multispecific antibodies that bind to LILRB1 and LILRB2, and uses thereof.

Claims32

Dependent claims

An antibody or antigen binding fragment thereof that binds LILRB1, wherein the antibody or antigen binding fragment comprises:

(1). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1155 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1156;
(2). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1157 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1158;
(3). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1159 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1160;
(4). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1161 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1162;
(5). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1163 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1164;
(6). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1165 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1166;
(7). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
283 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
284;
(8). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
285 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
286;
(9). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
287 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
288;
(10). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
289 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
290;
(11). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
291 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
292;
(12). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
293 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
294;
(13). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
295 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
296;
(14). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
297 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
298;
(15). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
299 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
300;
(16). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
301 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
302;
(17). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
303 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
304;
(18). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
305 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
306;
(19). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
307 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
308;
(20). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
309 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
310;
(21). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
311 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
312;
(22). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
313 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
314;
(23). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
315 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
316;
(24). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
317 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
318;
(25). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
319 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
320;
(26). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
321 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
322;
(27). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
323 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
324;
(28). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
325 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
326;
(29). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
327 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
328;
(30). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
329 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
330;
(31). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
331 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
332;
(32). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
333 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
334;
(33). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
335 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
336;
(34). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
337 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
338;
(35). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
339 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
340;
(36). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
341 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
342;
(37). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
343 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
344;
(38). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
345 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
346;
(39). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
347 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
348;
(40). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
349 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
350;
(41). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
351 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
352;
(42). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
353 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
354;
(43). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
355 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
356;
(44). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
357 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
358;
(45). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
359 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
360;
(46). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
361 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
362;
(47). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
363 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
364;
(48). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
365 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
366;
(49). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
367 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
368;
(50). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
369 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
370;
(51). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
371 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
372;
(52). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
373 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
374;
(53). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
375 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
376;
(54). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
377 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
378;
(55). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
379 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
380;
(56). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
381 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
382;
(57). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
383 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
384;
(58). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
385 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
386;
(59). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
387 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
388;
(60). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
389 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
390;
(61). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
391 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
392;
(62). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
393 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
394;
(63). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
395 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
396;
(64). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
397 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
398;
or
(65). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
399 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
400.

193 more elements

An antibody or antigen binding fragment thereof that binds LILRB2, wherein the antibody or antigen binding fragment comprises:

(1). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1167 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1168;
(2). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1169 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1170;
(3). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1171 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1172;
(4). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1173 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1174;
(5). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1175 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1176;
(6). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1177 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1178;
(7). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
401 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
402;
(8). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
403 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
404;
(9). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
405 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
406;
(10). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
407 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
408;
(11). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
409 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
410;
(12). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
411 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
412;
(13). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
413 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
414;
(14). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
415 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
416;
(15). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
417 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
418;
(16). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
419 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
420;
(17). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
421 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
422;
(18). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
423 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
424;
(19). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
425 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
426;
(20). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
427 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
428;
(21). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
429 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
430;
(22). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
431 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
432;
(23). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
433 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
434;
(24). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
435 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
436;
(25). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
437 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
438;
(26). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
439 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
440;
(27). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
441 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
442;
(28). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
443 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
444;
(29). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
445 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
446;
(30). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
447 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
448;
(31). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
449 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
450;
(32). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
451 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
452;
(33). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
453 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
454;
(34). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
455 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
456;
(35). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
457 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
458;
(36). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
459 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
460;
(37). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
461 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
462;
(38). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
463 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
464;
(39). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
465 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
466;
(40). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
467 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
468;
(41). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
469 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
470;
(42). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
471 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
472;
(43). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
473 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
474;
(44). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
475 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
476;
(45). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
477 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
478;
(46). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
479 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
480;
(47). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
481 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
482;
(48). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
483 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
484;
(49). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
485 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
486;
(50). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
487 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
488;
(51). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
489 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
490;
(52). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
491 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
492;
or
(53). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
493 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
494.

157 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/152,905Filed 1 Feb 2024
Priority: WO PCT/CN2023/0742762 Feb 2023
Published: 13 Aug 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61P 35/00
Antineoplastic agents
C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61P 37/02
Drugs for immunological or allergic disorders: immunomodulators
C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex

Family

No related US applications are recorded in the indexed filing history.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

An antibody or antigen binding fragment thereof that binds LILRB1, wherein the antibody or antigen binding fragment comprises:

(1). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1155 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1156;
(2). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1157 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1158;
(3). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1159 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1160;
(4). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1161 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1162;
(5). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1163 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1164;
(6). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
1165 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
1166;
(7). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
283 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
284;
(8). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
285 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
286;
(9). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
287 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
288;
(10). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
289 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
290;
(11). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
291 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
292;
(12). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
293 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
294;
(13). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
295 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
296;
(14). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
297 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
298;
(15). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
299 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
300;
(16). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
301 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
302;
(17). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
303 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
304;
(18). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
305 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
306;
(19). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
307 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
308;
(20). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
309 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
310;
(21). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
311 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
312;
(22). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
313 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
314;
(23). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
315 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
316;
(24). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
317 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
318;
(25). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
319 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
320;
(26). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
321 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
322;
(27). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
323 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
324;
(28). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
325 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
326;
(29). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
327 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
328;
(30). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
329 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
330;
(31). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
331 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
332;
(32). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
333 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
334;
(33). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
335 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
336;
(34). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
337 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
338;
(35). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
339 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
340;
(36). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
341 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
342;
(37). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
343 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
344;
(38). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
345 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
346;
(39). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
347 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
348;
(40). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
349 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
350;
(41). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
351 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
352;
(42). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
353 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
354;
(43). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
355 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
356;
(44). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
357 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
358;
(45). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
359 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
360;
(46). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
361 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
362;
(47). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
363 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
364;
(48). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
365 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
366;
(49). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
367 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
368;
(50). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
369 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
370;
(51). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
371 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
372;
(52). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
373 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
374;
(53). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
375 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
376;
(54). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
377 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
378;
(55). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
379 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
380;
(56). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
381 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
382;
(57). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
383 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
384;
(58). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
385 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
386;
(59). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
387 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
388;
(60). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
389 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
390;
(61). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
391 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
392;
(62). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
393 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
394;
(63). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
395 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
396;
(64). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
397 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
398;
or
(65). a HCDR1, a HCDR2, and a HCDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
399 and a LCDR1, a LCDR2, and a LCDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
400.

193 more elements

Facts

Application

19/152,905Filed 1 Feb 2024

Priority

WO PCT/CN2023/0742762 Feb 2023

Published

13 Aug 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61P 35/00
Antineoplastic agents
C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61P 37/02
Drugs for immunological or allergic disorders: immunomodulators
C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex